

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Tucatinib with trastuzumab and capecitabine for treating HER2-positive locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No potential equality issues have been identified.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

n/a

3. Has any change to the draft scope been agreed to highlight potential equality issues?

n/a

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

None identified.

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies

Issue date: February 2021

Approved by Associate Director (name):Janet Robertson.....

Date: 11 February 2021

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies

Issue date: February 2021